{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 0.9988905, "regularMarketPrice": 0.91, "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "exchange": "FRA", "shortName": "OREXO AB  SK-,40", "longName": "Orexo AB (publ)", "messageBoardId": "finmb_6021724", "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "firstTradeDateMilliseconds": 1541142000000, "priceHint": 4, "regularMarketChange": 0.009000003, "regularMarketTime": 1683892037, "regularMarketDayHigh": 0.91, "regularMarketDayRange": "0.871 - 0.91", "regularMarketDayLow": 0.871, "regularMarketVolume": 50, "regularMarketPreviousClose": 0.901, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "SEK", "regularMarketOpen": 0.871, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.039000034, "fiftyTwoWeekLowChangePercent": 0.04477616, "fiftyTwoWeekRange": "0.871 - 3.165", "fiftyTwoWeekHighChange": -2.2549999, "fiftyTwoWeekHighChangePercent": -0.71248025, "fiftyTwoWeekLow": 0.871, "fiftyTwoWeekHigh": 3.165, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.57, "sharesOutstanding": 34367600, "bookValue": 1.382, "fiftyDayAverage": 1.238, "fiftyDayAverageChange": -0.328, "fiftyDayAverageChangePercent": -0.26494345, "twoHundredDayAverage": 1.7022, "twoHundredDayAverageChange": -0.7922, "twoHundredDayAverageChangePercent": -0.46539772, "marketCap": 32951464, "priceToBook": 0.65846604, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "C5G.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Rapsgatan 7E", "city": "Uppsala", "country": "Sweden", "phone": "46 1 87 80 88 00", "fax": "46 1 87 80 88 88", "website": "https://www.orexo.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.", "fullTimeEmployees": 122, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nikolaj  Sorensen", "age": 50, "title": "Pres & CEO", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Fredrik  Jarrsten", "age": 55, "title": "Exec. VP & CFO", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cecilia  Coupland", "age": 46, "title": "Sr. VP & Head of Operations", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Lena  Wange", "title": "Investor Relations & Communications Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Robert  Ronn", "age": 46, "title": "Sr. VP and Head of R&D", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Edward  Kim M.B.A., M.D.", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Robert A. Deluca", "age": 61, "title": "Pres of Orexo US Inc", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jesper  Lind", "age": 62, "title": "Advisor", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 1, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 5, "governanceEpochDate": 1682899200, "maxAge": 86400}}], "error": null}}